Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer
These findings strongly suggest further clinical validation of this iRGD-modified BiTE-directed T-cell therapeutic approach, potentially offering a more effective treatment option for patients with pancreatic cancer and other solid tumors.
Authors
- Xinyuan Bai (ORCID: https://orcid.org/0000-0002-3900-9796)
- Jingjing Chen (ORCID: https://orcid.org/0000-0001-7535-8494)
- Wang Qiaoli (ORCID: https://orcid.org/0000-0003-3709-9166)
- Fanyan Meng (ORCID: https://orcid.org/0000-0003-1187-7644)
- Subiyinuer Tuerhong
- Juan Du (ORCID: https://orcid.org/0000-0002-7978-0665)
- Yingxin Wang (ORCID: https://orcid.org/0000-0001-9032-9990)
- Lu Zou (ORCID: https://orcid.org/0009-0008-2354-6002)
- Mengzhu Li
- Changchang Lu
- Qinghua Zheng
Institutions
- Nanjing Drum Tower Hospital (CN)
- Zhejiang University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1693755
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00